October 20, 2025- Plaintiffs and Defendant Novo Nordisks issued a joint request to extend the case management deadlines in the federal MDL
(143) summed up GLP-1R agonists to treat obesity and prevent cardiovascular disease
Andrews, a former congressman from New Jersey, helped author the Affordable Care Act while serving in the U.S
they may be the start of a new one
These findings may be relevant for health care professionals initiating tirzepatide in patients with T2D using antihypertensive medications, as this could be a potential opportunity to adjust antihypertensive medications if target blood pressure is reached
There was an underrepresentation of certain populations, such as women and Black, Asian, Hispanic or Latinos This trial positions semaglutide as a potentially beneficial treatment for reducing cardiovascular risk in patients with obesity and preexisting cardiovascular disease, highlighting its role beyond glucose control in diabetes management